Abstract
Autologous hematopoietic stem cell transplantation (aHSCT) has been repeatedly studied for treating multiple sclerosis (MS), yet evidence remains complicated as treatment was often administered to heterogenic patient collectives and in later stages of MS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
